A pyrrole-based natural small molecule mitigates HSP90 expression in MDA-MB-231 cells and inhibits tumor angiogenesis in mice by inactivating HSF-1
Related Experiment Video
Updated: Feb 26, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
K C Rashmi1, H S Atreya2, M Harsha Raj1
1Department of Studies in Biotechnology, University of Mysore, Mysuru, Karnataka, 570 006, India.
Abstract:
Heat shock proteins (HSPs), molecular chaperones, are crucial for the cancer cells to facilitate proper functioning of various oncoproteins involved in cell survival, proliferation, migration, and tumor angiogenesis. Tumor cells are said to be "addicted" to HSPs. HSPs are overexpressed in many cancers due to upregulation of transcription factor Heat-shock factor 1 (HSF-1), the multifaceted master regulator of heat shock response. Therefore, pharmacological targeting of HSPs via HSF-1 is an effective strategy to treat malignant cancers like triple negative breast cancer. In the current study, we evaluated the efficacy of a pyrrole derivative [bis(2-ethylhexyl)1H-pyrrole-3,4-dicarboxylate], TCCP, purified from leaves of Tinospora cordifolia for its ability to suppress heat shock response and angiogenesis using MDA-MB-231 cells and the murine mammary carcinoma: Ehrlich ascites tumor model. HSP90 was downregulated by TCCP by inactivation of HSF-1 resulting in inhibition of tumor cell proliferation, VEGF-induced cell migration, and concomitant decrease in tumor burden and neo-angiogenesis in vivo. The mechanism of suppression of HSPs involves inactivation of PI3K/Akt and phosphorylation on serine 307 of HSF-1 by the activation of ERK1. HSF-1 and HSP90 and 70 localization and expression were ascertained by immunolocalization, immunoblotting, and qPCR experiments. The anti-angiogenic effect of TCCP was studied in vivo in tumor-bearing mice and ex vivo using rat corneal micro-pocket assay. All the results thus corroborate the logic behind inactivating HSF-1 using TCCP as an alternative approach for cancer therapy.
Insights
Heat shock proteins (HSPs) drive cancer growth. A Tinospora cordifolia compound, TCCP, inhibits HSPs by targeting Heat-shock factor 1 (HSF-1), reducing tumor proliferation and angiogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Heat shock proteins (HSPs) are vital for cancer cell survival, proliferation, and angiogenesis.
- Tumor cells exhibit dependence on HSPs, often due to upregulated Heat-shock factor 1 (HSF-1).
- Targeting HSPs via HSF-1 presents a therapeutic strategy for cancers like triple-negative breast cancer.
Purpose of the Study:
- To evaluate the efficacy of TCCP, a pyrrole derivative from Tinospora cordifolia, in suppressing heat shock response and angiogenesis.
- To investigate TCCP's mechanism of action on HSF-1 and HSPs in cancer models.
Main Methods:
- Utilized MDA-MB-231 cells and an Ehrlich ascites tumor model.
- Assessed HSP90 downregulation, HSF-1 inactivation, and downstream effects on proliferation and migration.
- Employed immunolocalization, immunoblotting, qPCR, and in vivo/ex vivo angiogenesis assays.
Main Results:
- TCCP downregulated HSP90 by inactivating HSF-1, inhibiting tumor cell proliferation and VEGF-induced migration.
- Observed a decrease in tumor burden and neo-angiogenesis in vivo.
- Identified PI3K/Akt inactivation and ERK1-mediated HSF-1 phosphorylation as key mechanisms.
Conclusions:
- TCCP effectively suppresses heat shock response and angiogenesis by targeting HSF-1.
- Inactivating HSF-1 with TCCP offers a promising therapeutic approach for malignant cancers.
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules

